Related party transactions (Details Textual) - USD ($)	3 Months Ended		6 Months Ended		8 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Oct. 31, 2016
Merck Sharp & Dohme Corp [Member]
Related Party Transaction [Line Items]
Research and development agreement description			Under the agreement, Merck provided access to its archive of over 200,000 bacterial pathogens. The Company is initially performing molecular analyses on up to 10,000 pathogens to identify markers of resistance to support rapid decision making using the Acuitas Lighthouse, and to speed development of its rapid diagnostic products. Merck gains access to the high-resolution genotype data for the isolates as well as access to the Acuitas Lighthouse informatics to support internal research and development programs.
Maximum required amount to expend for procurement of materials						$ 175,000
Merck Sharp & Dohme Corp [Member] | Research and Development Expense [Member]
Related Party Transaction [Line Items]
Procurement costs recognized	$ 54,774		$ 113,907		$ 146,177
Fluidigm Corporation Supply Agreement [Member]
Related Party Transaction [Line Items]
Contractual agreement period			5 years
Additional contractual agreement period			5 years
Contractual agreement maturity date			Mar. 17, 2018
Contractual agreement description			The initial term of the Fluidigm Agreement is five years. Both parties have the ability to extend the term for an additional five years. Under the expanded Supply Agreement, the term was extended until March 17, 2018, and the Company has the right to extend the term of the Supply Agreement for up to two additional three-year terms.
Related party transaction, expenses from transactions with related party	0	$ 66,865	$ 44,721	$ 160,089
Related party transaction, purchases from related party	45,758	0	90,479	67,775
Payments to acquire equipment on lease	$ 30,254	$ 45,106	$ 60,517	$ 90,212